UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 189

Sortiert nach

Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis

BMC neurology, 2014-03, Vol.14 (1), p.58-58, Article 58

2014

Volltextzugriff (PDF)

Diagnostic workup for polyneuropathy

Schmerz (Berlin, Germany), 2024-06, Vol.38 (3), p.221-230

2024

Volltextzugriff (PDF)

Destruction of paranodal architecture in inflammatory neuropathy with anti-contactin-1 autoantibodies

Journal of neurology, neurosurgery and psychiatry, 2015-07, Vol.86 (7), p.720-728

2015

Volltextzugriff (PDF)

Autoantibodies against central nervous system antigens in a subset of B cell–dominant multiple sclerosis patients

Proceedings of the National Academy of Sciences - PNAS, 2020-09, Vol.117 (35), p.21512-21518

2020

Volltextzugriff (PDF)

Long-term management of multiple sclerosis patients treated with cladribine tablets beyond year 4

Expert opinion on pharmacotherapy, 2022-09, Vol.23 (13), p.1503-1510

2022

Volltextzugriff (PDF)

The Two-Minute Walk Test in Persons with Multiple Sclerosis: Correlations of Cadence with Free-Living Walking Do Not Support Ecological Validity

International journal of environmental research and public health, 2020-12, Vol.17 (23), p.9044

2020

Volltextzugriff (PDF)

Rehabilitation in multiple sclerosis: the role of tele-rehabilitation/gaming

Neurodegenerative disease management, 2016-12, Vol.6 (6s), p.17-18

Mäurer, Mathias

2016

Volltextzugriff (PDF)

Anti-pan-neurofascin antibodies induce subclass-related complement activation and nodo-paranodal damage

Brain (London, England : 1878), 2023-05, Vol.146 (5), p.1932-1949

2023

Volltextzugriff (PDF)

Patient-reported benefits from nabiximols treatment in multiple sclerosis-related spasticity exceed conventional measures

Neurodegenerative disease management, 2024-02, Vol.14 (1), p.11-20

2024

Volltextzugriff (PDF)

Long-term management of multiple sclerosis patients treated with cladribine tablets: an expert opinion

Expert opinion on pharmacotherapy, 2020-11, Vol.21 (16), p.1965-1969

2020

Volltextzugriff (PDF)

Internet-Supported Physical Exercise Training for Persons with Multiple Sclerosis-A Randomised, Controlled Study

International journal of molecular sciences, 2016-10, Vol.17 (10), p.1667-1667

2016

Volltextzugriff (PDF)

Validity of Consumer Activity Monitors and an Algorithm Using Smartphone Data for Measuring Steps during Different Activity Types

International journal of environmental research and public health, 2020-12, Vol.17 (24), p.9314

2020

Volltextzugriff (PDF)

TAURUS-MS II: real-world use of teriflunomide in Germany and changes in treatment patterns over time

Therapeutic advances in neurological disorders, 2024-01, Vol.17, p.17562864241252722-17562864241252722

2024

Volltextzugriff (PDF)

Cutaneous Adverse Events Associated with Interferon-[beta] Treatment of Multiple Sclerosis

International journal of molecular sciences, 2015-07, Vol.16 (7), p.14951

2015

Volltextzugriff (PDF)

Alemtuzumab as rescue therapy in a cohort of 50 relapsing–remitting MS patients with breakthrough disease on fingolimod: a multi-center observational study

Journal of neurology, 2018-07, Vol.265 (7), p.1521-1527

2018

Volltextzugriff (PDF)

Interferon beta and vitamin D synergize to induce immunoregulatory receptors on peripheral blood monocytes of multiple sclerosis patients

PloS one, 2014-12, Vol.9 (12), p.e115488-e115488

2014

Volltextzugriff (PDF)

Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany—Updated series of 120 cases

International journal of stroke, 2020-08, Vol.15 (6), p.609-618

2020

Volltextzugriff (PDF)

Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy

Annals of neurology, 2014-12, Vol.76 (6), p.792-801

2014

Volltextzugriff (PDF)

Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS

Neurology, 2015-07, Vol.85 (1), p.29

2015

Volltextzugriff (PDF)

OzEAN Study to Collect Real-World Evidence of Persistent Use, Effectiveness, and Safety of Ozanimod Over 5 Years in Patients With Relapsing-Remitting Multiple Sclerosis in Germany

Frontiers in neurology, 2022-06, Vol.13, p.913616-913616

2022

Volltextzugriff (PDF)

New master's program: multiple sclerosis management

Wiener medizinische Wochenschrift, 2022-11, Vol.172 (15-16), p.383-391

2022

Volltextzugriff (PDF)

The enteric nervous system is a potential autoimmune target in multiple sclerosis

Acta neuropathologica, 2017-08, Vol.134 (2), p.281-295

2017

Volltextzugriff (PDF)

A PD-1 polymorphism is associated with disease progression in multiple sclerosis

Annals of neurology, 2005-07, Vol.58 (1), p.50-57

2005

Volltextzugriff (PDF)

Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF

Multiple sclerosis, 2015-07, Vol.21 (8), p.1036-1044

2015

Volltextzugriff (PDF)

Mental Health in Multiple Sclerosis Patients without Limitation of Physical Function: The Role of Physical Activity

International journal of molecular sciences, 2015-07, Vol.16 (7), p.14901-14911

2015

Volltextzugriff (PDF)

1 – 25 von 189

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(85)
Mit Volltextzugriff
(157)

Publikationsform

Artikel
(124)
Buchkapitel
(52)
Bücher
(9)
Reviews
(4)

Sprache

Deutsch
(131)
Englisch
(56)
Japanisch
(6)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(5)
... seit 90 Tagen
(7)

Menü

Weitere Dienste

Einstellungen

Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis

Diagnostic workup for polyneuropathy

Destruction of paranodal architecture in inflammatory neuropathy with anti-contactin-1 autoantibodies

Autoantibodies against central nervous system antigens in a subset of B cell–dominant multiple sclerosis patients

Long-term management of multiple sclerosis patients treated with cladribine tablets beyond year 4

The Two-Minute Walk Test in Persons with Multiple Sclerosis: Correlations of Cadence with Free-Living Walking Do Not Support Ecological Validity

Rehabilitation in multiple sclerosis: the role of tele-rehabilitation/gaming

Anti-pan-neurofascin antibodies induce subclass-related complement activation and nodo-paranodal damage

Patient-reported benefits from nabiximols treatment in multiple sclerosis-related spasticity exceed conventional measures

Long-term management of multiple sclerosis patients treated with cladribine tablets: an expert opinion

Internet-Supported Physical Exercise Training for Persons with Multiple Sclerosis-A Randomised, Controlled Study

Validity of Consumer Activity Monitors and an Algorithm Using Smartphone Data for Measuring Steps during Different Activity Types

TAURUS-MS II: real-world use of teriflunomide in Germany and changes in treatment patterns over time

Cutaneous Adverse Events Associated with Interferon-[beta] Treatment of Multiple Sclerosis

Alemtuzumab as rescue therapy in a cohort of 50 relapsing–remitting MS patients with breakthrough disease on fingolimod: a multi-center observational study

Interferon beta and vitamin D synergize to induce immunoregulatory receptors on peripheral blood monocytes of multiple sclerosis patients

Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany—Updated series of 120 cases

Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy

Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS

OzEAN Study to Collect Real-World Evidence of Persistent Use, Effectiveness, and Safety of Ozanimod Over 5 Years in Patients With Relapsing-Remitting Multiple Sclerosis in Germany

New master's program: multiple sclerosis management

The enteric nervous system is a potential autoimmune target in multiple sclerosis

A PD-1 polymorphism is associated with disease progression in multiple sclerosis

Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF

Mental Health in Multiple Sclerosis Patients without Limitation of Physical Function: The Role of Physical Activity

Suchergebnisse filtern